2018
DOI: 10.1111/tri.13273
|View full text |Cite
|
Sign up to set email alerts
|

Upregulation of CD80 on glomerular podocytes plays an important role in development of proteinuria following pig-to-baboon xeno-renal transplantation - an experimental study

Abstract: We have previously reported that co-transplantation of the kidney with vascularized donor thymus from α-1,3-galactosyltransferase gene knockout pigs with an anti-CD154 with rituximab-based regimen led to improved xenograft survival in baboons with donor-specific unresponsiveness. However, nephrotic syndrome emerged as a complication in which the glomeruli showed mild mesangial expansion with similarities to minimal change disease (MCD) in humans. Since MCD is associated with CD80 expression in glomeruli and el… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

2
48
1

Year Published

2019
2019
2022
2022

Publication Types

Select...
4
3

Relationship

3
4

Authors

Journals

citations
Cited by 29 publications
(51 citation statements)
references
References 40 publications
(86 reference statements)
2
48
1
Order By: Relevance
“…We hypothesized that a regimen which includes the anti‐CD20 monoclonal antibody (mAb) rituximab might prevent proteinuria, as it is known to bind to SMPDL3b on porcine podocytes. In addition, similar to clinical minimal change disease (MCD), CD80 on glomerular podocytes was upregulated following XKTx + VT, without histologic and immunologic evidence of rejection . By adding rituximab at the time of revascularization of porcine kidney grafts to mask SMPDL3b as well as a weekly dose of CTLA4‐Ig, we were able to reduce proteinuria and improve survival of a recipient of a GalTKO thymokidney for up to 193 days .…”
Section: Introductionmentioning
confidence: 83%
See 1 more Smart Citation
“…We hypothesized that a regimen which includes the anti‐CD20 monoclonal antibody (mAb) rituximab might prevent proteinuria, as it is known to bind to SMPDL3b on porcine podocytes. In addition, similar to clinical minimal change disease (MCD), CD80 on glomerular podocytes was upregulated following XKTx + VT, without histologic and immunologic evidence of rejection . By adding rituximab at the time of revascularization of porcine kidney grafts to mask SMPDL3b as well as a weekly dose of CTLA4‐Ig, we were able to reduce proteinuria and improve survival of a recipient of a GalTKO thymokidney for up to 193 days .…”
Section: Introductionmentioning
confidence: 83%
“…In order to resolve this major obstacle, we have sought to elucidate the causes of early proteinuria in our XKTx + VT model. Our recent data indicated that sphingomyelin phosphodiesterase‐3 (SMPDL3b) and upregulation of CD80 expression on podocytes in porcine kidney grafts in nephrotic baboons were likely contributors . We hypothesized that a regimen which includes the anti‐CD20 monoclonal antibody (mAb) rituximab might prevent proteinuria, as it is known to bind to SMPDL3b on porcine podocytes.…”
Section: Introductionmentioning
confidence: 99%
“…Using these two techniques, we have demonstrated that vascularized thymic tissue can successfully induce tolerance and support thymopoiesis across fully allogeneic barriers in MGH miniature swine . By extending this strategy to pig‐to‐baboon models, we have recently achieved survival of a life‐supporting TK for over 6 months . Notably, multiple recipients bearing a functional TK for over 3 months developed donor‐specific unresponsiveness at the T‐ and B‐cell levels .…”
Section: Introductionmentioning
confidence: 99%
“…[23][24][25] By extending this strategy to pig-to-baboon models, we have recently achieved survival of a life-supporting TK for over 6 months. 26 Notably, multiple recipients bearing a functional TK for over 3 months developed donor-specific unresponsiveness at the Tand B-cell levels. 26,27 Although new thymic emigrants (CD4 + /CD31 + / CD45 + ) were developed (Yamada et al manuscript in preparation) beyond 2 months following transplantation, we have not yet been able to fully stop immunosuppression, although we have been successful with tapering it markedly.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation